MEDINET Co., Ltd. (2370) AI Stock Analysis

• Market Cap: ¥8.54B
• Dividend Yield: N/A
• Average Volume (3M): 1.57M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 5.44%
• EPS Growth: -2.17%
• Country: JP
• Employees: 92
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.28
• Shares Outstanding: 275,517,330
• 10 Day Avg. Volume: 1,137,840
• 30 Day Avg. Volume: 1,567,416
• PEG Ratio: -3.12
• Price to Book (P/B): 2.45
• Price to Sales (P/S): 11.43
• P/FCF Ratio: -6.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ¥31.00 ▲(6.90% Upside)
• Action: Reiterated Date: 01/07/26
• Date: Action: Reiterated 01/07/26

The score is held down primarily by very weak financial performance driven by ongoing large losses and deteriorating free cash flow, despite low leverage. Technicals are mixed with modest near-term strength but a still-weak trend signal (negative MACD), and valuation is constrained by losses and lack of dividend support.

Positive Factors

Recurring & diversified revenue streams

MEDINET's mix of hardware sales plus software, maintenance, training and partnership revenue builds recurring income from installed systems. This durable business model increases revenue visibility, supports higher lifetime customer value and cushions hardware cyclicality for months ahead.

Recent top-line growth

Reported FY2025 revenue growth of ~11.8% indicates sustained demand for its imaging and diagnostic solutions. Consistent top-line momentum can enable scale, support R&D investment and help absorb fixed costs, improving the odds of eventual margin recovery if cost structure is addressed.

Conservative leverage profile

A virtually debt-free balance sheet materially reduces solvency and interest-service risk, giving management flexibility to fund operations, pursue strategic partnerships or obtain financing on better terms. This conservatism is a durable buffer while profitability is restored.

Negative Factors

Persistent large losses

Net margin near -168% in FY2025 reflects deep, sustained losses that erode equity and restrict reinvestment capacity. Structural unprofitability suggests issues with pricing, cost base or product mix; absent a credible path to sustained profits, the company will need financing or major operational changes.

Severe cash burn and negative free cash flow

Consistently negative operating and free cash flow, with FY2025 FCF plunging ~780% vs FY2024, indicates losses are translating into real cash outflows. Persistent cash burn depletes reserves, forces external financing and can divert management focus from product execution to fundraising over the medium term.

Eroding margins and shareholder equity

Sharp gross margin decline from ~37% to ~13.5% alongside shareholder equity falling from ~¥5.51B to ~¥3.78B signals weakening pricing power or rising costs. Margin compression and capital erosion reduce investment capacity, worsen returns and increase the likelihood of future funding needs.

MEDINET Co., Ltd. Business Overview & Revenue Model

Company Description

MEDINET Co., Ltd. operates as a contract development and manufacturing organization that provides regenerative medicine and cell therapy solutions in Japan. Its solutions include technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy. The company also manufactures regenerative medical/investigational and specified cell products. In addition, its value chain solutions include personnel training, facility and equipment design, facility operations and management, preparation of standard operating procedures, logistics network, information system, purchasing and production management, quality management system, quality control and assurance, and technology transfer and process development solutions. Further, the company supports medical institutions, research institutions, and biopharmaceutical companies to conduct immuno-cell therapy. MEDINET Co., Ltd. was incorporated in 1995 and is headquartered in Tokyo, Japan.

How the Company Makes Money

MEDINET generates revenue primarily through the sale of its medical imaging systems and diagnostic tools, which are utilized by hospitals and clinics across various healthcare settings. The company also earns income from software solutions that enhance medical workflows and data management. Additional revenue streams include maintenance services, training programs for healthcare staff, and partnerships with healthcare institutions for joint ventures in research and development. Significant collaborations with medical device manufacturers and technology firms further boost its earnings by expanding its market reach and enhancing product offerings.

MEDINET Co., Ltd. Financial Statement Overview

Summary

Despite FY2025 revenue growth (+11.8%) and effectively no debt, results are dominated by persistent large losses (net margin ~-168%), sharply lower gross margin versus prior years, and worsening free cash flow with ongoing cash burn alongside declining equity—raising funding and execution risk.

Income Statement

Revenue has grown recently (up 11.8% in FY2025 after modest growth in FY2024), but profitability remains very weak. Gross margin has trended down versus earlier years (about 13.5% in FY2025 vs. 37.2% in FY2020), and the company continues to post large operating and net losses (net margin around -168% in FY2025). Losses have not meaningfully narrowed over time, limiting earnings quality and visibility.

Balance Sheet

The balance sheet is conservatively levered with effectively no debt (debt-to-equity near zero across periods), which reduces solvency risk. However, shareholder equity has declined meaningfully (from ~¥5.51B in FY2022 to ~¥3.78B in FY2025) and returns on equity remain negative, reflecting ongoing losses and potential continued erosion of capital if the business does not improve.

Cash Flow

Cash generation is a key weakness: operating cash flow and free cash flow are consistently negative, and FY2025 free cash flow deteriorated sharply (down ~780% vs. FY2024). Cash burn broadly tracks reported losses (free cash flow roughly in line with net loss), suggesting losses are translating into real cash outflows rather than being primarily non-cash.

Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	724.63M	810.29M	768.50M	661.54M	633.67M	683.03M
Gross Profit	128.40M	109.72M	82.67M	98.25M	127.92M	180.42M
EBITDA	-1.30B	-1.26B	-1.16B	-1.33B	-1.17B	-718.52M
Net Income	-1.41B	-1.36B	-1.28B	-1.44B	-1.25B	-843.39M
Balance Sheet
Total Assets	6.35B	4.25B	5.70B	5.63B	6.08B	5.38B
Cash, Cash Equivalents and Short-Term Investments	5.03B	3.17B	4.65B	4.40B	4.50B	4.10B
Total Debt	91.32M	0.00	781.00K	2.31M	4.30M	7.69M
Total Liabilities	548.63M	476.50M	509.27M	590.20M	566.14M	474.95M
Stockholders Equity	5.80B	3.78B	5.19B	5.04B	5.51B	4.90B
Cash Flow
Free Cash Flow	211.20M	-1.44B	-1.33B	-1.35B	-1.20B	-1.01B
Operating Cash Flow	211.20M	-1.41B	-1.27B	-1.26B	-1.16B	-974.70M
Investing Cash Flow	0.00	-565.17M	65.14M	3.27M	-20.23M	344.25M
Financing Cash Flow	0.00	-2.55M	1.46B	1.16B	1.58B	1.08B

MEDINET Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 29.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2370, the sentiment is Negative. The current price of 29 is below the 20-day moving average (MA) of 31.05, below the 50-day MA of 30.64, and below the 200-day MA of 33.69, indicating a neutral trend. The MACD of 0.32 indicates Negative momentum. The RSI at 48.38 is Neutral, neither overbought nor oversold. The STOCH value of 20.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2370.

MEDINET Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2385	58 Neutral	¥7.06B	40.70	―	2.08%	-10.24%	―
2342	56 Neutral	¥5.25B	-6.73	―	―	-0.77%	-288.43%
206A	54 Neutral	¥8.13B	-8.70	―	―	―	―
2183	52 Neutral	¥7.25B	-4.09	―	5.44%	-15.42%	-879.08%
4974	52 Neutral	¥138.12B	-19.18	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2370	46 Neutral	¥8.54B	-6.05	―	―	5.44%	-2.17%

MEDINET Co., Ltd. Corporate Events

MEDINET Widens Losses but Maintains Strong Equity Base in Q1 FY2026

MEDINET Co., Ltd. reported first-quarter net sales of ¥181 million for the period ended December 2025, down 11.4% year-on-year, continuing a decline from the prior year’s 17.7% drop. The company remained loss-making, with an operating loss of ¥371 million and a net loss of ¥339 million, resulting in a basic loss per share of ¥1.28.

Despite ongoing losses, MEDINET maintains a strong equity position, with an equity ratio of 86.4% and net assets of ¥3,428 million against total assets of ¥3,954 million as of December 2025. Management continues to forgo shareholder returns in the near term, with the dividend per share for the second quarter forecast at ¥0.00, underscoring a priority on capital preservation amid weak top-line performance.

The most recent analyst rating on (JP:2370) stock is a Hold with a Yen32.00 price target. To see the full list of analyst forecasts on MEDINET Co., Ltd. stock, see the JP:2370 Stock Forecast page.